These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 24527759)

  • 1. The increase in BIK expression following ERK1/2 pathway inhibition is a consequence of G₁ cell-cycle arrest and not a direct effect on BIK protein stability.
    Sale MJ; Cook SJ
    Biochem J; 2014 May; 459(3):513-24. PubMed ID: 24527759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MEK1/2 inhibitors potentiate UCN-01 lethality in human multiple myeloma cells through a Bim-dependent mechanism.
    Pei XY; Dai Y; Tenorio S; Lu J; Harada H; Dent P; Grant S
    Blood; 2007 Sep; 110(6):2092-101. PubMed ID: 17540843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Src tyrosine kinase inhibits apoptosis through the Erk1/2- dependent degradation of the death accelerator Bik.
    Lopez J; Hesling C; Prudent J; Popgeorgiev N; Gadet R; Mikaelian I; Rimokh R; Gillet G; Gonzalo P
    Cell Death Differ; 2012 Sep; 19(9):1459-69. PubMed ID: 22388352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncogenic BRAF(V600E) inhibits BIM expression to promote melanoma cell survival.
    Cartlidge RA; Thomas GR; Cagnol S; Jong KA; Molton SA; Finch AJ; McMahon M
    Pigment Cell Melanoma Res; 2008 Oct; 21(5):534-44. PubMed ID: 18715233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CDK1, not ERK1/2 or ERK5, is required for mitotic phosphorylation of BIMEL.
    Gilley R; Lochhead PA; Balmanno K; Oxley D; Clark J; Cook SJ
    Cell Signal; 2012 Jan; 24(1):170-80. PubMed ID: 21924351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells.
    Kang J; Sergio CM; Sutherland RL; Musgrove EA
    BMC Cancer; 2014 Jan; 14():32. PubMed ID: 24444383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The BH3 mimetic ABT-263 synergizes with the MEK1/2 inhibitor selumetinib/AZD6244 to promote BIM-dependent tumour cell death and inhibit acquired resistance.
    Sale MJ; Cook SJ
    Biochem J; 2013 Mar; 450(2):285-94. PubMed ID: 23234544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim.
    Nikrad M; Johnson T; Puthalalath H; Coultas L; Adams J; Kraft AS
    Mol Cancer Ther; 2005 Mar; 4(3):443-9. PubMed ID: 15767553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells.
    Little AS; Balmanno K; Sale MJ; Newman S; Dry JR; Hampson M; Edwards PA; Smith PD; Cook SJ
    Sci Signal; 2011 Mar; 4(166):ra17. PubMed ID: 21447798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nitrogen-containing bisphosphonates induce apoptosis of hematopoietic tumor cells via inhibition of Ras signaling pathways and Bim-mediated activation of the intrinsic apoptotic pathway.
    Tsubaki M; Itoh T; Satou T; Imano M; Komai M; Ogawa N; Mukai J; Nishida S
    Biochem Pharmacol; 2013 Jan; 85(2):163-72. PubMed ID: 23085435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Up-regulation of pro-apoptotic protein Bim and down-regulation of anti-apoptotic protein Mcl-1 cooperatively mediate enhanced tumor cell death induced by the combination of ERK kinase (MEK) inhibitor and microtubule inhibitor.
    Kawabata T; Tanimura S; Asai K; Kawasaki R; Matsumaru Y; Kohno M
    J Biol Chem; 2012 Mar; 287(13):10289-10300. PubMed ID: 22270368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BIK is involved in BRAF/MEK inhibitor induced apoptosis in melanoma cell lines.
    Borst A; Haferkamp S; Grimm J; Rösch M; Zhu G; Guo S; Li C; Gao T; Meierjohann S; Schrama D; Houben R
    Cancer Lett; 2017 Sep; 404():70-78. PubMed ID: 28720543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. c-Cbl is not required for ERK1/2-dependent degradation of BimEL.
    Wiggins CM; Band H; Cook SJ
    Cell Signal; 2007 Dec; 19(12):2605-11. PubMed ID: 17884340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-level expression of proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukemia: role of BCR/ABL, characterization of underlying signaling pathways, and reexpression by novel pharmacologic compounds.
    Aichberger KJ; Mayerhofer M; Krauth MT; Vales A; Kondo R; Derdak S; Pickl WF; Selzer E; Deininger M; Druker BJ; Sillaber C; Esterbauer H; Valent P
    Cancer Res; 2005 Oct; 65(20):9436-44. PubMed ID: 16230407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma.
    Ou DL; Shen YC; Liang JD; Liou JY; Yu SL; Fan HH; Wang DS; Lu YS; Hsu C; Cheng AL
    Clin Cancer Res; 2009 Sep; 15(18):5820-8. PubMed ID: 19737956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BIM(EL), an intrinsically disordered protein, is degraded by 20S proteasomes in the absence of poly-ubiquitylation.
    Wiggins CM; Tsvetkov P; Johnson M; Joyce CL; Lamb CA; Bryant NJ; Komander D; Shaul Y; Cook SJ
    J Cell Sci; 2011 Mar; 124(Pt 6):969-77. PubMed ID: 21378313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of lenalidomide with vitamin D3 induces apoptosis in mantle cell lymphoma via demethylation of BIK.
    Brosseau C; Dousset C; Touzeau C; Maïga S; Moreau P; Amiot M; Le Gouill S; Pellat-Deceunynck C
    Cell Death Dis; 2014 Aug; 5(8):e1389. PubMed ID: 25165875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MEK1/2 inhibitor withdrawal reverses acquired resistance driven by BRAF
    Sale MJ; Balmanno K; Saxena J; Ozono E; Wojdyla K; McIntyre RE; Gilley R; Woroniuk A; Howarth KD; Hughes G; Dry JR; Arends MJ; Caro P; Oxley D; Ashton S; Adams DJ; Saez-Rodriguez J; Smith PD; Cook SJ
    Nat Commun; 2019 May; 10(1):2030. PubMed ID: 31048689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PINCH-1 regulates the ERK-Bim pathway and contributes to apoptosis resistance in cancer cells.
    Chen K; Tu Y; Zhang Y; Blair HC; Zhang L; Wu C
    J Biol Chem; 2008 Feb; 283(5):2508-17. PubMed ID: 18063582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Colorectal cancer cells with the BRAF(V600E) mutation are addicted to the ERK1/2 pathway for growth factor-independent survival and repression of BIM.
    Wickenden JA; Jin H; Johnson M; Gillings AS; Newson C; Austin M; Chell SD; Balmanno K; Pritchard CA; Cook SJ
    Oncogene; 2008 Dec; 27(57):7150-61. PubMed ID: 18806830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.